Scarica l'app Stockscreener
9.80
4.70%
0.44
Pre-mercato:
9.53
-0.27
-2.76%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$9.36
Aprire:
$9.47
Volume 24 ore:
737.79K
Relative Volume:
1.27
Capitalizzazione di mercato:
$519.08M
Reddito:
$8.78M
Utile/perdita netta:
$-104.70M
Rapporto P/E:
-4.135
EPS:
-2.37
Flusso di cassa netto:
$-82.68M
1 W Prestazione:
+12.90%
1M Prestazione:
-16.10%
6M Prestazione:
-27.84%
1 anno Prestazione:
+98.78%
Intervallo 1D:
$9.30
$9.815
Intervallo di 1 settimana:
$8.8113
$9.815
Portata 52W:
$4.09
$17.58
Stoke Therapeutics Inc Stock (STOK) Company Profile
Nome
Stoke Therapeutics Inc
Settore
Industria
Telefono
781-430-8200
Indirizzo
45 WIGGINS AVENUE, BEDFORD, MA
Confronta STOK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
9.80 | 519.08M | 8.78M | -104.70M | -82.68M | -2.37 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-20 | Iniziato | Chardan Capital Markets | Buy |
| 2024-10-14 | Ripresa | Leerink Partners | Outperform |
| 2024-03-26 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | Ripresa | JP Morgan | Neutral |
| 2023-07-25 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-04-26 | Ripresa | Canaccord Genuity | Buy |
| 2023-01-06 | Downgrade | BofA Securities | Buy → Underperform |
| 2022-10-24 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | Iniziato | Jefferies | Buy |
| 2021-12-03 | Iniziato | BofA Securities | Buy |
| 2021-11-22 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-05-18 | Iniziato | UBS | Neutral |
| 2021-05-10 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-02-10 | Downgrade | Wedbush | Outperform → Neutral |
| 2020-12-15 | Ripresa | H.C. Wainwright | Buy |
| 2020-12-11 | Reiterato | Needham | Buy |
| 2020-10-23 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-09-29 | Ripresa | JP Morgan | Neutral |
| 2020-09-29 | Iniziato | Needham | Buy |
| 2019-12-18 | Iniziato | Wedbush | Outperform |
| 2019-11-12 | Iniziato | BTIG Research | Buy |
| 2019-10-25 | Iniziato | H.C. Wainwright | Buy |
| 2019-07-15 | Iniziato | Canaccord Genuity | Buy |
| 2019-07-15 | Iniziato | Cowen | Outperform |
| 2019-07-15 | Iniziato | Credit Suisse | Outperform |
| 2019-07-15 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Stoke Therapeutics Inc Borsa (STOK) Ultime notizie
Brokers Offer Predictions for STOK FY2025 Earnings - MarketBeat
Possible Signal As Stoke Therapeutics Insiders Sell US$523k In Stock - Simply Wall St
Is it a Good Idea to Invest in Stoke Therapeutics Stock Now? - MSN
When the Price of (STOK) Talks, People Listen - Stock Traders Daily
Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Acquired by Assenagon Asset Management S.A. - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Stock Price Up 9.7%Time to Buy? - MarketBeat
Barclays PLC Raises Stock Position in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Is Stoke Therapeutics Inc (NASDAQ: STOK) Still Trending? - Stocks Register
Q1 EPS Estimates for Stoke Therapeutics Raised by Wedbush - Defense World
Head-To-Head Contrast: Inhibitor Therapeutics (OTCMKTS:INTI) and Stoke Therapeutics (NASDAQ:STOK) - Defense World
Stoke Therapeutics Inc (STOK): Worth A Small Bite At $8.92 - Stocks Register
Wedbush Equities Analysts Raise Earnings Estimates for STOK - MarketBeat
What is Wedbush’s Estimate for STOK FY2029 Earnings? - Defense World
Research Analysts Offer Predictions for STOK FY2029 Earnings - MarketBeat
Learn to Evaluate (STOK) using the Charts - Stock Traders Daily
Stoke Therapeutics to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
Analyst maintains OW rating on Stoke Therapeutics as P3 EMPEROR study design finalized - Investing.com Canada
Needham & Company LLC Reiterates "Buy" Rating for Stoke Therapeutics (NASDAQ:STOK) - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Receives "Buy" Rating from HC Wainwright - MarketBeat
The Analyst Verdict: Stoke Therapeutics In The Eyes Of 4 Experts - Benzinga
Tenvie raises $200M for brain drug R&D; Sana spikes on single patient’s results - Yahoo Finance
Stoke Therapeutics (NASDAQ:STOK) Shares Gap DownTime to Sell? - MarketBeat
Stoke Therapeutics Gains Regulatory Alignment for Phase 3 Study - TipRanks
STOKStoke Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Stoke Therapeutics aligns with regulators on Dravet study - Investing.com
Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome - Business Wire
Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet Syndrome - Business Wire
Brokerages Set Stoke Therapeutics, Inc. (NASDAQ:STOK) Target Price at $21.29 - MarketBeat
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Stoke Therapeutics Advances First Disease-Modifying Dravet Syndrome Treatment to Phase 3 - StockTitan
Franklin Resources Inc. Cuts Position in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Geode Capital Management LLC Boosts Stock Position in Stoke Therapeutics, Inc. (NASDAQ:STOK) - MarketBeat
Geode Capital Management LLC Buys 76,661 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Barclays PLC Purchases 47,239 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Stoke Therapeutics, Inc. (NASDAQ:STOK) Stock Holdings Lifted by Barclays PLC - MarketBeat
When (STOK) Moves Investors should Listen - Stock Traders Daily
Skorpios Trust Reduces Stake in Stoke Therapeutics Inc - GuruFocus.com
Stoke therapeutics sees $23 million stock sale by Skorpios Trust - Investing.com Canada
The Zacks Analyst Blog Highlights ADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDex - Yahoo Finance
Stoke Therapeutics (NASDAQ:STOK) Trading Down 2.9%Should You Sell? - MarketBeat
4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to Grow - Yahoo Finance
Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Purchased by State Street Corp - Defense World
State Street Corp Grows Stake in Stoke Therapeutics, Inc. (NASDAQ:STOK) - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Shares Gap Down – What’s Next? - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Cuts Stock Position in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Chardan Capital Initiates Coverage of Stoke Therapeutics (STOK) with Buy Recommendation - MSN
Stoke Therapeutics (NASDAQ:STOK) Now Covered by Chardan Capital - MarketBeat
Jane Street Group LLC Acquires 255,028 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - MarketBeat
(STOK) Proactive Strategies - Stock Traders Daily
Stoke Therapeutics (NASDAQ:STOK) Trading Down 5%What's Next? - MarketBeat
Stoke Therapeutics Inc Azioni (STOK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):